

# Corporate Growth Plan by the New Management



RaQualia  
innovators for life

# Message from the New Management

We will push forward our drug discovery to deliver innovative new drugs to patients, will boost our corporate value, and will make RaQualia the most advanced venture company of the drug discovery. We appreciate your continued support.



Candidate for the new representative director

**Shuzo Watanabe**

# Growth Strategy by New Management Team to Increase the Corporate Value

To be a globally competitive R&D bio-venture



Continuously generate seeds of innovative new drugs



Implement early-stage clinical development for in-house programs to maximize future revenue

# Growth Plan by New Management Team to Increase the Corporate Value



RaQualia  
innovators for life

1

Strengthen the capability of the ion-channel drug-discovery

2

Implement early-stage development

3

Strengthen the collaboration with academia

4

Accelerate overseas activities

5

Improve the probability of success



Seeds of new drugs

Note: This document has not been prepared for the purpose of soliciting investments. Investors are advised to make their own judgments when making investments. Also, please be sure to refer to the precautions at the end of the last page of this document.

# Growth Plan by New Management Team to Increase the Corporate Value



RaQualia  
innovators for life

## 1 Strengthen the capability of the ion-channel drug-discovery

**Further strengthen the platform of ion-channel drug-discovery through technology collaborations**

- Cutting edge structural biology approaches (cryo-electron microscopy, etc.)
- New modalities (antibodies, etc.)
- Drug discovery process by AI

## 2 Implement early-stage development

**In order to maximize future revenue, conduct early-stage clinical development for selected programs**

- Ghrelin receptor agonist (RQ-00433412) for preclinical tests
- The clinical development of tegoprazan in Japan: under discussion with HK inno.N Corp.
- Another option of clinical development of tegoprazan in Japan: self development by RaQualia utilizing South Korean clinical data

Note: This document has not been prepared for the purpose of soliciting investments. Investors are advised to make their own judgments when making investments. Also, please be sure to refer to the precautions at the end of the last page of this document.

# Growth Plan by New Management Team to Increase the Corporate Value

3

## Strengthen the collaboration with academia

### Further strengthen the academic cooperation in the Chubu region

- New collaboration with Gifu Pharmaceutical University : enhance the ability to search ideas for new drugs in the Chubu region (Central Japan)

4

## Accelerate overseas activities

### Enhance the activities of U.S. Branch

- Evaluation of new collaboration projects and in-licensing technologies for drug discovery
- Out-licensing of our IP

5

## Improve the probability of success

### Improve the probability of R&D success

- Translational advisory board with external experts: optimize the processes of target selection, drug discovery research and development

# Implementation of the strategic portfolio



Key factor for our growth is the continuous generation of “**Seeds of new drugs**”.

**Establish a balanced portfolio by considering the risks and benefits of the programs**

## **In-house R&D programs**

Programs mainly focusing on ion channels that are potential candidate for in-house development


## **Joint research programs (Industry)**

Programs with industrial companies that have unique technologies to enhance RaQualia’s drug-discovery capability and possibility to generate “Seeds of new drugs”

## **Joint research programs (Academia)**

Programs aiming to generate “Seeds of first-in-class drugs” from ideas of promising targets, not-limited to ion channels

# The History and Future Growth of RaQualia Pharma



Note: This document has not been prepared for the purpose of soliciting investments. Investors are advised to make their own judgments when making investments. Also, please be sure to refer to the precautions at the end of the last page of this document.



# The Mission of RaQualia Pharma



Deliver innovative new drugs to patients from RaQualia Pharma as soon as possible

# Precautions Regarding Forward-looking Statements



- The materials and information provided in this presentation include so-called "forward-looking statements". These are based on current expectations, forecasts and risk assumptions and contain uncertainties that could lead to results that are substantially different from these statements.
- These risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rates and currency exchange fluctuations. Risks and uncertainties are particularly present in forward-looking statements related to products (R&D programs and compounds). Product risks and uncertainties include, but are not limited to, the following: technological advances, patent acquisition by competitors, completion of clinical trials, complaints and concerns about product safety and efficacy, regulatory approvals, domestic and international medical insurance system reform, the tendency to curb medical expenses, government laws and regulations affecting domestic and overseas businesses, and issues associated with new product development.
- Even if there is new information in the future, or future events occur, RaQualia is under no obligation to update or revise the "forward-looking statements" contained in this presentation.

Note: This document has not been prepared for the purpose of soliciting investments. Investors are advised to make their own judgments when making investments. Also, please be sure to refer to the precautions at the end of the last page of this document.



RaQualia  
innovators for life